MarketCap
Facebook
X
TelegramQuarterly report 2025-Q1
added 05-08-2026
Cumberland Pharmaceuticals Interest Expense 2011-2026 | CPIX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Cumberland Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 496 K | 606 K | 668 K | 586 K | 98 K | 264 K | 246 K | 196 K | 92.9 K | 106 K | 73.9 K | 67.1 K | 103 K | 72 K | 353 K | 1.42 M | 773 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.42 M | 67.1 K | 366 K |
Quarterly Interest Expense Cumberland Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 110 K | 110 K | 85.8 K | - | 137 K | 126 K | 119 K | - | 110 K | 193 K | 186 K | - | 149 K | 138 K | 120 K | - | 20 K | 25.9 K | 24.4 K | - | 75.2 K | 119 K | 33.1 K | - | 64.9 K | 217 K | 60.9 K | - | 19.2 K | 22 K | 18.3 K | - | 8.9 K | 30 K | 31.7 K | - | 29.1 K | 28.2 K | 20.4 K | - | 19.8 K | 18.5 K | 15.6 K | - | 26.9 K | 12.3 K | 12.2 K | - | 24.3 K | 20.7 K | 17.7 K | - | 17.2 K | 16.7 K | 22.4 K | - | 33.4 K | 79.6 K | 216 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 217 K | 8.9 K | 66.3 K |
Interest Expense of other stocks in the Drug manufacturers industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Endo International plc
ENDP
|
350 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
501 K | - | - | $ 36.6 M |  USA |
 |
HEXO Corp.
HEXO
|
20.1 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
134 K | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
2.4 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
6.65 K | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-27.9 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
1.42 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
10.2 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
-241 K | $ 2.68 | -2.55 % | $ 1.03 B | Canada |
 |
Athenex
ATNX
|
25.8 M | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
47 K | $ 37.64 | -0.03 % | $ 1.38 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
13 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
-4 M | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
4.04 M | - | -39.89 % | $ 27.7 M | USA |
 |
Canopy Growth Corporation
CGC
|
74.6 M | $ 1.0 | -0.99 % | $ 108 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-5 K | $ 2.34 | -1.68 % | $ 297 M | USA |
 |
Pacira BioSciences
PCRX
|
-373 K | $ 22.99 | -1.58 % | $ 1.06 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-10 K | $ 1.09 | -0.91 % | $ 1.35 M | USA |
 |
Solid Biosciences
SLDB
|
824 K | $ 7.14 | -1.11 % | $ 625 M | USA |
 |
Jupiter Wellness
JUPW
|
152 K | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
58 M | - | 1.15 % | $ 7.11 M | USA |
 |
Tilray
TLRY
|
46.6 M | $ 4.98 | -2.73 % | $ 3.08 B | Canada |
 |
cbdMD
YCBD
|
34.3 K | $ 0.69 | -1.72 % | $ 2.78 M | USA |
 |
Evolus
EOLS
|
-539 K | $ 6.73 | 3.38 % | $ 434 M | USA |
 |
Sundial Growers
SNDL
|
81 K | $ 1.42 | -2.74 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
54.2 M | $ 8.32 | -0.83 % | $ 445 M | USA |
 |
Veru
VERU
|
768 K | $ 3.0 | -7.98 % | $ 43.9 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
12 K | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
2.78 M | $ 23.48 | 0.04 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
-174 K | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
18.3 M | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
-142 M | $ 5.06 | -1.94 % | $ 1.88 B | Canada |
 |
PetIQ
PETQ
|
38.3 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.15 M | $ 6.65 | 1.99 % | $ 263 M | USA |
 |
Recro Pharma
REPH
|
9.96 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
19.5 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
3.13 M | $ 4.23 | -0.35 % | $ 211 M | USA |
 |
Viatris
VTRS
|
471 M | $ 16.48 | 1.04 % | $ 19.2 B | USA |
 |
Zomedica Corp.
ZOM
|
-144 K | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
27 K | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-623 K | $ 0.62 | 0.35 % | $ 22.3 M | USA |
 |
Tricida
TCDA
|
17.6 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
27.3 K | $ 0.71 | -6.82 % | $ 3.05 M |  China |
 |
TherapeuticsMD
TXMD
|
300 K | $ 2.2 | 20.88 % | $ 25.5 M | USA |